1 Recommendations
Closed for comments This consultation ended on at Request commenting lead permission
2 Information about ponesimod
Marketing authorisation indication
2.1 Ponesimod (Ponvory, Janssen) is indicated for 'the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features'.
Dosage in the marketing authorisation
2.2 The dosage schedule for ponesimod is available in the summary of product characteristics.
Price
2.3 The list price for ponesimod is commercial in confidence so cannot be reported here. The company has a commercial arrangement, which would have applied if the technology had been recommended.
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions
Question on Consultation
Question on Consultation
Question on Consultation
Question on Consultation